{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T19:18:14Z","timestamp":1747163894400,"version":"3.40.5"},"reference-count":5,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","canadianjournalofophthalmology.ca","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Ophthalmology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.jcjo.2024.03.018","type":"journal-article","created":{"date-parts":[[2024,4,14]],"date-time":"2024-04-14T21:00:14Z","timestamp":1713128414000},"page":"e630-e632","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Omalizumab-induced ocular myasthenia gravis?"],"prefix":"10.1016","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-2270-9060","authenticated-orcid":false,"given":"Hanru","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devaraj","family":"Supramaniam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9777-3250","authenticated-orcid":false,"given":"Sudha","family":"Cugati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7723-4812","authenticated-orcid":false,"given":"Celia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcjo.2024.03.018_bib0001","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3389\/fnmol.2020.00156","article-title":"Pathomechanisms and clinical implications of myasthenic syndromes exacerbated and induced by medical treatments","volume":"13","author":"Krenn","year":"2020","journal-title":"Front Mol Neurosci"},{"key":"10.1016\/j.jcjo.2024.03.018_bib0002","unstructured":"Australian Government, Department of Health, Therapeutic Goods Administration. Australian public assessment report for omalizumab (rch). Available at: www.tga.gov.au\/sites\/default\/files\/auspar-omalizumab-rch-160622.pdf. Accessed November 01, 2023."},{"key":"10.1016\/j.jcjo.2024.03.018_bib0003","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1111\/bcp.13338","article-title":"Ocular myasthenic syndrome, adverse reaction to omalizumab? A case report","volume":"83","author":"Kalteren","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jcjo.2024.03.018_bib0004","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jim.2008.10.015","article-title":"Trace level analysis of leached Protein A in bioprocess samples without interference from the large excess of rhMAh IgG","volume":"341","author":"Zhu-Shimoni","year":"2009","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.jcjo.2024.03.018_bib0005","unstructured":"Bird SJ. Overview of the treatment of myasthenia gravis. UpToDate. Available at: www.uptodate.com\/contents\/overview-of-the-treatment-of-myasthenia-gravis?search=managment%20of%20MG&source=search_result&selectedTitle=1\u223c150&usage_type=default&display_rank=1#H3162488928. Accessed November 01, 2023."}],"container-title":["Canadian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418224001005?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418224001005?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T17:51:16Z","timestamp":1726595476000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008418224001005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":5,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0008418224001005"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjo.2024.03.018","relation":{},"ISSN":["0008-4182"],"issn-type":[{"type":"print","value":"0008-4182"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Omalizumab-induced ocular myasthenia gravis?","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjo.2024.03.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}